Tutto DSpace

Mostra i principali dati dell'item

Anti-Ro52 antibody is highly prevalent and a marker of better prognosis in patients with ovarian cancer

dc.creatorBogdanos D.P., Gkoutzourelas A., Papadopoulos V., Liaskos C., Patrikiou E., Tsigalou C., Saratziotis A., Hajiioannou J., Scheper T., Meyer W., Sakkas L.I., Papandreou C.en
dc.date.accessioned2023-01-31T07:38:45Z
dc.date.available2023-01-31T07:38:45Z
dc.date.issued2021
dc.identifier10.1016/j.cca.2021.07.006
dc.identifier.issn00098981
dc.identifier.urihttp://hdl.handle.net/11615/71758
dc.description.abstractBackground and Aims: Anti-Ro52 antibody (Ab) reactivity is highly prevalent in autoimmune rheumatic diseases (ARDs), mainly Sjögren's syndrome (SjS) and systemic lupus erythematosus (SLE), but also in other inflammatory disorders. Thorough assessment of the prevalence, clinical significance and epitope specificity of Ro52-autoAbs in cancerous diseases is still lacking. Material and Methods: Anti-Ro52 Ab reactivity was tested in a large cohort of 490 patients with various malignant diseases. Ro52-autoAb epitope mapping by an in house line immunoassay was carried out using 5 recombinant Ro52 polypeptides spanning Ro52. Results: Anti-Ro52 abs were significantly more prevalent in patients with ovarian cancer (30%) compared to patients with 6 other malignant diseases (median 8.1%, range 5.9–15.8%). The presence of anti-Ro52 abs in patients with ovarian cancer was strongly associated with better overall survival. Ro52 epitope mapping of patients with ovarian cancer was dissimilar to that of SLE and SjS ARDs, less frequently recognizing Ro52-1 and Ro52-4 fragments compared to patients with SLE and SjS. Conclusion: We demonstrate for first time an unexpectedly high frequency of anti-Ro52 abs in patients with ovarian cancer, their presence indicating better overall survival. Their distinguishing epitope profile may suggest a non-SLE or SjS-related stimulus for autoAb production. © 2021en
dc.language.isoenen
dc.sourceClinica Chimica Actaen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85111179822&doi=10.1016%2fj.cca.2021.07.006&partnerID=40&md5=139dc6cc3dd6aaddf821d07084ed71f7
dc.subjectautoantibodyen
dc.subjectepitopeen
dc.subjectRo52 antibodyen
dc.subjectunclassified drugen
dc.subjectautoantibodyen
dc.subjectautoantigenen
dc.subjectribonucleoproteinen
dc.subjectadulten
dc.subjectantibody productionen
dc.subjectArticleen
dc.subjectautoimmune diseaseen
dc.subjectautoimmunityen
dc.subjectcancer patienten
dc.subjectcancer prognosisen
dc.subjectcohort analysisen
dc.subjectfemaleen
dc.subjecthumanen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectovary canceren
dc.subjectoverall survivalen
dc.subjectparaneoplastic syndromeen
dc.subjectprevalenceen
dc.subjectrheumatic diseaseen
dc.subjectovary tumoren
dc.subjectprognosisen
dc.subjectSjoegren syndromeen
dc.subjectsystemic lupus erythematosusen
dc.subjectAutoantibodiesen
dc.subjectAutoantigensen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLupus Erythematosus, Systemicen
dc.subjectOvarian Neoplasmsen
dc.subjectPrognosisen
dc.subjectRibonucleoproteinsen
dc.subjectSjogren's Syndromeen
dc.subjectElsevier B.V.en
dc.titleAnti-Ro52 antibody is highly prevalent and a marker of better prognosis in patients with ovarian canceren
dc.typejournalArticleen


Files in questo item

FilesDimensioneFormatoMostra

Nessun files in questo item.

Questo item appare nelle seguenti collezioni

Mostra i principali dati dell'item